Therapeutic Activity of Chemical Compounds or Medicinal Preparations

Matches 401 - 450 out of 93,019	< 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 >

Document	Document Title
WO/2023/204397A1	PHARMACEUTICAL COMPOSITION COMPRISING ACETYLSALICYLIC ACID AND PROTON PUMP INHIBITOR The present invention relates to a pharmaceutical composition comprising: a first unit including acetylsalicylic acid or a pharmaceutically acceptable salt thereof; and a second unit comprising a proton pump inhibitor. The pharmaceutical...
WO/2023/203197A1	METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING STROKE Stroke is the second cause of death and the first cause of adult disability in industrialized countries. The goal of emergency therapy for acute ischemic stroke is prompt restoration of blood flow to regions of brain that are ischemic bu...
WO/2023/204698A1	DIAGNOSIS AND/OR TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION The present invention relates to compositions and methods for treating and/or preventing heart failure with preserved ejection fraction (HFpEF), especially in subjects with an impaired NO-cGMP-PKG signalling axis. The inventors establish...
WO/2023/202582A1	GPCR REGULATOR AND USE THEREOF A compound of a GPR132 regulator, a pharmaceutically acceptable salt or ester, a prodrug, a stereoisomer, a hydrate, a solvate, a crystal form, or a metabolite form thereof, as well as a preparation method therefor and medicinal use ther...
WO/2023/205099A2	SMALL MOLECULE INDUCERS OF CARDIOMYOCYTES TO IMPROVE CARDIAC STRUCTURE AND FUNCTION Here, we describe an infant with congenital dilated cardiomyopathy (cDCM) whose impaired cardiac function and disrupted sarcomere and mitochondria structures were modeled using induced pluripotent stem cells (iPSCs). The causal gene enco...
WO/2023/204292A1	COMPOUND, ALDEHYDE DEHYDROGENASE 2 ACTIVATOR, PHARMACEUTICAL COMPOSITION, AND TREATMENT AND/OR PREVENTATIVE DRUG A compound represented by formula (1) [where: A is a heterocyclic ring; R1 and R2 are each independently hydrogen, an alkyl, an alkenyl, or an alkynyl; R3 is an alkyl, an alkenyl, or an alkynyl; L is an alkylene or is not present; X1 is ...
WO/2023/205465A1	HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of us...
WO/2023/202583A1	FXR REGULATOR AND USE THEREOF Disclosed are an FXR regulator and use thereof, and specifically disclosed are a compound represented by formula I, or a stereoisomer, a prodrug, a crystal form, a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, ...
WO/2023/202383A1	TETRAHYDROTHIENOPYRIDINE DEUTERATED DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF Disclosed in the present invention are a tetrahydrothienopyridine deuterated derivative, a preparation method therefor, and pharmaceutical use thereof. The derivative can be used for preparing a medicament for the prevention or treatment...
WO/2023/202102A1	USE OF SESQUITERPENOID COMPOUND IN INHIBITING TRPA1 CHANNEL ACTIVITY The present invention relates to the technical field of biomedicine, it has been found in the present invention that a compound shown in formula I, or an optical isomer or racemate thereof, or a solvate thereof, or a pharmaceutically acc...
WO/2023/204291A1	BICYCLOAMINE CARBOXAMIDE DERIVATIVE The present invention relates to a compound represented by formula (1) or a pharmaceutically acceptable salt thereof that has therapeutic and prophylactic effects on diseases in which orexin type 2 receptors participate, specifically, na...
WO/2023/205183A1	ISTAROXIME-CONTAINING INTRAVENOUS FORMULATION FOR THE TREATMENT OF PRE-CARDIOGENIC SHOCK AND CARDIOGENIC SHOCK Compositions for intravenous infusion of istaroxime in human patients suffering from pre-cardiogenic shock or cardiogenic shock are disclosed. Likewise, methods of administering istaroxime to individuals exhibiting symptoms of, or having...
WO/2023/201851A1	MUTANT OF SMALL MOLECULAR CHAPERONE PROTEIN MOG1-ENCODING GENE AND USE THEREOF Provided are a mutant of a small molecular chaperone protein MOG1-encoding gene and use thereof. The mutant is more effective than a wild-type MOG1 in enhancing myocardial sodium current, and the mutant of the small molecular chaperone p...
WO/2023/205217A1	METHOD FOR CARDIAC REPAIR This disclosure provides methods to modulate cardiac regeneration in a mammalian cardiac cell or progenitor, comprising contacting the mammalian cardiac cell with a DOT1L gene modulator.
WO/2023/205243A1	DETERMINING RISK OF FIBROMUSCULAR DYSPLASIA AND SYSTEMS AND METHODS OF USE THEREOF Provided herein are systems and methods for determining a subject's risk of fibromuscular dysplasia (FMD) and/or abdominal aortic aneurysm (AAA), and methods of treatment and symptom management based thereon.
WO/2023/203177A1	ANTIBODIES OR ANTIGEN-BINDING FRAGMENTS PAN-SPECIFICALLY BINDING TO GREMLIN-1 AND GREMLIN-2 AND USES THEREOF The invention relates to antibodies, or antigen-binding fragments thereof, pan- specifically binding to Gremlin-1 and Gremlin-2. The antibodies described herein may be humanized antibodies and/or deimmunized antibodies. Means and methods...
WO/2023/205463A1	HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of us...
WO/2023/201998A1	APPLICATION OF HYDROXYBETULINIC ACID COMPOUND IN PREPARATION OF DRUGS FOR SKIN DISEASES The present invention relates to a skin medication technology, and in particular to an application of a hydroxybetulinic acid compound in treatment of skin diseases, especially eczema, inflammatory skin diseases, and allergic shock. Acco...
WO/2023/202687A1	PYRAZINONE DERIVATIVE AND USE THEREOF IN MEDICINE The present invention relates to a compound as represented by general formula (A) or a stereoisomer, a deuterated substance, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or a cocrystal thereof, an intermediate t...
WO/2023/204511A1	COMPOSITION FOR PREVENTING OR TREATING VALVULAR CALCIFICATION The present invention provides a pharmaceutical composition or food composition for preventing, alleviating or treating valvular calcification.
WO/2023/203235A1	COMPOSITE MATRIX USED FOR PROMOTING INNERVATION, OSTEOGENESIS AND ANGIOGENESIS Provided is a composite material used for promoting innervation, osteogenesis and angiogenesis.
WO/2023/202477A1	DIHYDROMYRICETIN TETRAHYDROPYRROLE COMPLEX AND PREPARATION METHOD THEREFOR, AND APPLICATION Disclosed are a dihydromyricetin tetrahydropyrrole complex and a preparation method therefor, and an application. The molecular formula of the dihydromyricetin tetrahydropyrrole complex is as shown in formula (I). The preparation method ...
WO/2023/205778A1	HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of us...
WO/2023/205468A1	HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of us...
WO/2023/202686A1	COMPOSITION AND METHOD FOR INHIBITING XANTHINE DEHYDROGENASE (XDH) Provided are a xanthine dehydrogenase (XDH) dsRNA agent useful for reducing xanthine dehydrogenase (XDH) expression in cells and objects, and a composition thereof with a xanthine dehydrogenase XDH antisense polynucleotide reagent and/or...
WO/2023/200738A1	COMBINATION TREATMENT OF DILATED CARDIOMYOPATHY COMPRISING A TYROSINE KINASE INHIBITOR AND A STATIN Treatment of dilated cardiomyopathy in a subject by combination treatment with a tyrosine kinase inhibitor and a statin.
WO/2023/200002A1	PRODUCTION METHOD OF EXTRACELLULAR VESICLE POPULATION, AND EXTRACELLULAR VESICLE POPULATION The present invention provides a production method of an extracellular vesicle population containing extracellular vesicles on the membrane surface of which phosphatidylserine is low expressed, said method comprising: (1) a step for cult...
WO/2023/201308A1	GENE THERAPY FOR TREATING AN OCULAR DISEASE Provided herein are gene therapy methods for the treatment of diseases or disorders associated with the eye of a subject involving the use of recombinant adeno-associated viruses (rAAVs) comprising a variant AAV capsid to deliver a trans...
WO/2023/199258A1	SOLID STATE FORMS OF MAVACAMTEN AND PROCESS FOR PREPARATION THEREOF The present disclosure encompasses a solid state form of Mavacamten, in embodiments a crystalline polymorph of Mavacamten, processes for preparation thereof, and pharmaceutical compositions thereof.
WO/2023/197914A1	NOVEL USE OF PYRAZOLOPYRIMIDINE COMPOUND Provided is novel use of a compound of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, ester, acid, metabolite or prodrug thereof in preventing or treating hypersensitivity or an autoimmune inflammation-related disorder.
WO/2023/201207A1	ADENO-ASSOCIATED VIRUS WITH ENGINEERED CAPSID The present disclosure provides engineered capsid proteins and recombinant adeno-associated virus (rAAV) virions with an engineered capsid protein. In particular, the disclosure provides AAV9 virions with engineered AAV9 capsid, AAV5/9 c...
WO/2023/198141A1	COMPOUND CAPABLE OF REGULATING AND CONTROLLING ACTIVITY OF 15-PGDH, AND PREPARATION METHOD THEREFOR Disclosed are a compound of formula (I) capable of regulating and controlling the activity of 15-PGDH, or a stereoisomer thereof, a tautomer thereof or a mixture thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereo...
WO/2023/198055A1	POLYMORPH OF 7,8-DIHYDROXYFLAVONE, AND PREPARATION METHOD THEREFOR A polymorph of 7,8-dihydroxyflavone, and a preparation method therefor. The polymorph of 7,8-dihydroxyflavone has significantly improved physicochemical properties, and thus has a higher medicinal value.
WO/2023/199244A1	COMPOSITION COMPRISING N-ACETYLCYSTEINE, VITAMIN D AND PREFERABLY GLUTATHIONE, USES THEREOF, AND PHARMACEUTICAL AND NUTRACEUTICAL COMPOSITIONS THEREOF It is an object of the present invention a composition comprising N-acetylcysteine, or a pharmaceutically or food grade acceptable salt thereof or a derivative thereof, and a vitamin D, preferably vitamin D3 and/or vitamin D2, and prefer...
WO/2023/200122A1	PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETIC STROKE, CONTAINING RAGE ANTAGONIST AND AGE SCAVENGER The present invention relates to a pharmaceutical composition for preventing or treating diabetic stroke, containing at least one from among a receptor for advanced glycation endproducts (RAGE) antagonist and an advanced glycation endpro...
WO/2023/151653A9	OLEOGEL AND PREPARATION METHOD THEREFOR AND USE THEREOF An oleogel and a preparation method therefor and a use thereof. The oleogel comprises 60-90 wt% of liquid oil, 6-35 wt% of a structuring agent, and 4-15 wt% of water. The liquid oil comprises an unsaturated fatty acid, and the structurin...
WO/2023/198140A1	HETEROCYCLIC GLP-1 AGONISTS The present disclosure relates generally to GLP-1 agonists and pharmaceutical compositions comprising the same, as well as methods for treating a GLP-1 associated disease, disorder, or condition.
WO/2023/169115A9	AAV VECTOR HAVING HIGH AFFINITY WITH NERVOUS SYSTEM, AND APPLICATION THEREOF The present invention relates to an adeno-associated virus (AAV) capsid protein having a high affinity with a nervous system, an AAV vector comprising the capsid protein, and an application thereof. The AAV capsid protein has a good affi...
WO/2023/196412A1	LIQUID FORMULATIONS COMPRISING MITOGEN-ACTIVATED PROTEIN KINASE KINASE (MEK) INHIBITORS AND METHODS USING SAME The present disclosure provides compositions comprising a Mitogen-Activated Protein Kinase Kinase (MEK) inhibitor. In certain embodiments, the MEK inhibitor is binimetinib. In certain embodiments, the MEK inhibitor is ATR-002 (zapnometin...
WO/2023/196804A1	USE OF APOLIPOPROTEIN A-V AS AN ORAL INGESTIBLE PROTEIN FOR NUTRACEUTICAL OR PHARMACEUTICAL APPLICATIONS The present disclosure provides methods of treating hypertriglyceridemia, atherosclerosis, or cardiovascular disease, the methods comprising administering to a subject in need thereof a therapeutically effective amount of apolipoprotein ...
WO/2023/196890A1	MODIFIED SOPHOROLIPID FOR IMPROVED BIOAVAILABILITY OF AMINO ACIDS AND METHOD OF USE The present invention provides modified sophorolipids modified with amino acids to improve, e.g., the bioavailability of the amino acids. The modified sophorolipids of the present invention are capable of efficiently delivering the amino...
WO/2023/195535A1	ANTIBODY BINDING TO FIBRIN, FIBRINOLYTIC PROTEIN CONTAINING ANTIBODY, AND PHARMACEUTICAL FORMULATION CONTAINING PROTEIN The present invention provides: a stable fibrin clot-soluble protein excellent in production in protein-expressing cells in a serum-free medium and suppressing the production of impurities such as degradation products; a pharmaceutical f...
WO/2023/194214A1	BENZIMIDAZOLE DERIVATIVES FOR PULMONARY ARTERIAL HYPERTENSION The invention relates to a compound of the formula (II) and to the metal complexes, salts, enantiomers, enantiomer mixtures, diastereomers, diastereomer mixtures, tautomers, hydrates, solvates, racemates, dimers, or oligomers thereof in ...
WO/2023/194213A1	INOBRODIB FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION The present invention describes a compound of formula (II) and its metal complexes, salts, enantiomers, enantiomer mixtures, diastereomers, diastereomer mixtures, tautomers, hydrates, solvates, racemates, dimers or oligomers in a medical...
WO/2023/193733A1	AT2R AGONIST The present disclosure relates to the field of medicine. Specifically, provided in the present disclosure are a compound represented by formula I, and a tautomer, a stereoisomer, a hydrate, a solvate, and a pharmaceutically acceptable sa...
WO/2023/194798A1	METHODS FOR TREATING LEUKOCYTOSIS, ENDOTHELIAL DYSFUNCTION AND CARDITIS USING LIPID BINDING PROTEIN-BASED COMPLEXES Methods for treating leukocytosis, endothelial dysfunction, and carditis comprising administering to a subject a lipid binding protein-based complex.
WO/2023/193694A1	SAFE AND STABLE NIMODIPINE FORMULATION FOR INJECTION AND METHOD FOR PREPARING SAME The present invention relates to the technical field of pharmaceutics, and in particular, to a safe and stable nimodipine formulation for injection and a method for preparing same. The present invention provides a lyophilized nimodipine-...
WO/2023/195509A1	VASCULAR ENDOTHELIAL BARRIER FAILURE INHIBITOR AND USE THEREOF This vascular endothelial barrier failure inhibitor contains, as an active ingredient, a claudin-5 expression inducer, a nucleic acid coding claudin-5, or claudin-5.
WO/2023/196820A2	TREATMENT OF ENPP1 DEFICIENCY AND ABCC6 DEFICIENCY The present disclosure provides, among other things, specific doses of an ENPP1 agent for in vivo treatment of an ENPP1 deficiency, such as for treatment of Generalized Arterial Calcification of Infancy (GACI), Autosomal Recessive Hypoph...
WO/2023/196898A1	BETA GLOBIN MIMETIC PEPTIDES AND THEIR USE Disclosed is an isolated polypeptide comprising a Hbb peptide, wherein the Hbb peptide comprises one of: a) X1PEEX2SAX3X4AX5WX6K, (SEQ ID NO: 1) wherein X1 is T or S, X2 is K or R, X3 is a hydrophobic amino acid, X4 is T, S, or a hydroph...

Matches 401 - 450 out of 93,019	< 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 >